retatrutide for diabetes type 2 🩺 in diabetes: TRANSCEND-T2D-1 Phase 3 results → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly Medscape | The investigational triple

The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm

Modulacin del Sistema Cardiovascular: La influencia benfica de los anlogos de receptores de GLP-1 se extiende ms all de su impacto en el control glucmico, abarcando una modulacin favorable del sistema cardiovascular

It also suggests that even if you don't feel immediate digestive upset, the antibiotic is still interacting with your gut environment in a complex way

The availability of specialist physicians and integrated care pathways supports the widespread dispensing of long-acting GLP-1 therapies through hospital channels

Titration the practice of starting at a low dose and gradually increasing it over several weeks is a standard approach with incretin-based therapies, as it allows the gastrointestinal system to adjust and reduces the severity of nausea, vomiting, and other early side effects